🇺🇸 FDA
Pipeline program

Tuvusertib (M1774) in Participants with Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

MS201924_0001

Phase 1 other active

Quick answer

Tuvusertib (M1774) in Participants with Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) for Metastatic or Locally Advanced Unresectable Solid Tumors is a Phase 1 program (other) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Metastatic or Locally Advanced Unresectable Solid Tumors
Phase
Phase 1
Modality
other
Status
active

Clinical trials